Skip to main content

Marc Hodosh, Aravinda Chakravarti, David Valle, David Barker, Bruce Basarab

Premium
The X Prize Foundation has hired Marc Hodosh as senior director to lead the $10 million Archon X Prize for genomics, which will be awarded to a research team that is successfully able to map 100 human genomes in 10 days. Hodosh is the former president of ID One, a facial recognition technology company, and also served as director of business development at Viisage Technology, a biometric and secure ID company. He was most recently a consultant to inventor Dean Kamen at DEKA Research & Development and also chairs Kamen's FIRST Robotics competition in Boston. 
 
"Marc's impressive facility with engineering and technology coupled with his experience spearheading large-scale scientific competitions will be critical to driving the Archon X Prize for genomics competition," said Tom Vander Ark, president of the X Prize Foundation, in a statement.
 
Hodosh has a BA in psychology and neuroscience from Ithaca College and a master’s in medicine from BostonUniversityMedicalSchool.
 

 
Aravinda Chakravarti is stepping down as director of the McKusick-Nathans Institute of Genetic Medicine at Johns Hopkins University in order to lead the IGM’ new Center for Complex Disease Genomics, where he will “use genomic methods to clarify the molecular underpinnings of common diseases, including birth defects, hypertension, sudden cardiac death, and autism,” according to a Hopkins statement.
 
David Valle will replace Chakravarti at the helm of the IGM. Valle currently leads the Center for Inherited Disease Research and the Predoctoral Training Program in Human Genetics at Hopkins. He is a past president of the American Society of Human Genetics, a member of the board of scientific overseers of the Jackson Laboratory, and a member of the Institute of Medicine of the National Academies.
 

 
David Barker, who recently retired as vice president and chief scientific officer of Illumina, has joined NextBio’s board of directors. Barker joined Illumina in March 2000. Prior to that, he was vice president and chief science advisor at Amersham Biosciences (now GE Healthcare) and vice president of research and business development at Molecular Dynamics, which was acquired by Amersham.
 

 
Orchid Cellmark has appointed Bruce Basarab as vice president of North American sales and marketing, a newly created position. Before joining Orchid Cellmark, Basarab was executive vice president of commercial operations for medical device company i-STAT. Prior to that, he was senior vice President of sales and marketing for Geneva Pharmaceuticals, the US generic drug unit of Novartis. Basarab previously served at Ciba-Geigy, first as executive director of Northwest sales and later vice president of sales for the company’s pharmaceutical division.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.